Compass Therapeutics, Inc. - Common Stock (CMPX)
1.6900
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 3rd, 7:49 AM EDT
Detailed Quote
Previous Close | 1.690 |
---|---|
Open | - |
Bid | 1.640 |
Ask | 1.670 |
Day's Range | N/A - N/A |
52 Week Range | 0.7650 - 4.080 |
Volume | 10,348 |
Market Cap | 215.45M |
PE Ratio (TTM) | -24.14 |
EPS (TTM) | -0.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 2,036,367 |
About Compass Therapeutics, Inc. - Common Stock (CMPX)
Compass Therapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and other serious diseases. The company focuses on harnessing the power of the immune system to create novel treatment options that target specific pathways involved in tumor growth and immune response. By employing a combination of advanced technologies and comprehensive research, Compass Therapeutics aims to deliver transformative medicines that improve patient outcomes and address unmet medical needs in oncology. Their pipeline includes a range of therapeutic candidates that are designed to enhance the immune system's ability to fight cancer effectively. Read More
News & Press Releases
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Via Chartmill · April 2, 2025
Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients.
Via Benzinga · April 1, 2025
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via Chartmill · March 31, 2025
Via Benzinga · March 31, 2025

Via Benzinga · February 24, 2025

Via Benzinga · February 19, 2025

Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.
Via MarketBeat · February 4, 2025

CMPX stock results show that Compass Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024

Via Benzinga · June 10, 2024

CMPX stock results show that Compass Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 13, 2024

Via Benzinga · May 1, 2024

Via Benzinga · April 26, 2024

Via Benzinga · April 25, 2024

The 10X penny stocks discussed here are a much more reliable investment than many other alternatives investors are likely to encounter.
Via InvestorPlace · March 24, 2024

CMPX stock results show that Compass Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 21, 2024

Via Benzinga · March 13, 2024

Via Benzinga · March 5, 2024

Via Benzinga · February 27, 2024

Via Benzinga · January 17, 2024

These are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation.
Via InvestorPlace · October 13, 2023

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) rose 65.3% to $12.20 in pre-market trading after gaining around 9% on Friday.
Via Benzinga · September 5, 2023

Via Benzinga · August 1, 2023

Via Benzinga · July 31, 2023